Wuhan Hiteck Biological Pharma Co Ltd (300683) — Cash Flow-to-Debt Ratio
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of CN¥-17.49 Million could theoretically repay 0% of its total liabilities (CN¥393.09 Million) in one year. See 300683 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wuhan Hiteck Biological Pharma Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Wuhan Hiteck Biological Pharma Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see Wuhan Hiteck Biological Pharma Co Ltd (300683) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Wuhan Hiteck Biological Pharma Co Ltd. Check Wuhan Hiteck Biological Pharma Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | CN¥22.69 Million | CN¥525.05 Million | ▲ +286.8% |
| 2023 | 0.01x | CN¥5.31 Million | CN¥475.73 Million | ▼ -92.2% |
| 2022 | 0.14x | CN¥53.03 Million | CN¥371.20 Million | ▲ +318.9% |
| 2021 | 0.03x | CN¥12.09 Million | CN¥354.46 Million | ▲ +179.9% |
| 2020 | -0.04x | CN¥-19.70 Million | CN¥461.62 Million | ▼ -127.7% |
| 2019 | 0.15x | CN¥63.03 Million | CN¥409.03 Million | ▼ -6.4% |
| 2018 | 0.16x | CN¥73.42 Million | CN¥445.77 Million | ▼ -47.3% |
| 2017 | 0.31x | CN¥83.08 Million | CN¥265.62 Million | ▼ -27.0% |
| 2016 | 0.43x | CN¥143.86 Million | CN¥335.87 Million | ▼ -26.1% |
| 2015 | 0.58x | CN¥159.89 Million | CN¥275.74 Million | ▲ +13.4% |
| 2014 | 0.51x | CN¥135.40 Million | CN¥264.78 Million | ▲ +24.1% |
| 2013 | 0.41x | CN¥76.82 Million | CN¥186.42 Million | — |